ACC 2019

Letter from the Editor

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Patients with polyvascular disease significantly undertreated with lipid lowering therapies

DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups

Superior outcomes of DES compared with BMS in very elderly population

Diagnosing cardiac sarcoidosis with endomyocardial biopsies

Substantial impact of temporary interruptions of warfarin versus DOAC

Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin

Smartwatch can detect atrial fibrillation with high degree of accuracy

Higher incidence arrhythmia post-percutaneous closure of secundum ASD in patients >60 years

Unplanned hospital readmission is common after congenital cardiac surgery

Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications

BNP still a reliable prognostic marker before and during sacubitril/valsartan treatment

High 5-year survival rates for older HF patients without initial severe comorbidity

Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism

Treatment patterns PAH have changed recently

TAVR superior and non-inferior to SAVR in low-risk patients

Immediate angiography not better than delayed angiography in non-STEMI cardiac arrest patients

Ticagrelor monotherapy safe after dual antiplatelet therapy

P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT

Similar MACE rates but higher all-cause mortality in PAD patients with diabetes

Lower rates stroke/SE with DOACs in frail non-valvular AF patients

Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry

Convincing evidence of the role of icosapent in reducing subsequent CV events

Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients

Early discharge and home treatment feasible for low-risk pulmonary embolism patients